EQRX EQRx, Inc.
EQRx Inc is a biotechnology company. Its pipeline programs include two pre-registrational oncology assets that have shown assuring Phase 3 data (aumolertinib and sugemalimab), and multiple other clinical-stage programs.
$2.60 +0.14 (5.49%)
As of 02/02/2023 09:54:51 EST IEX book CBOE book
Security Information
Category1:
US EquityCategory2:
Common stocksCategory3:
Small cap
GICS sector: Health Care
Industry: Biotechnology
Index country: USA
Country of incorporation:
IPO date: 12/15/2021
Outstanding shares: 488,433,373
Average volume: 4,226,871
Market cap: $1,142,934,093
Current dividend yield: 0.00%
All SEC filings:
SEC Edgar Online
Quarterly filings:
10-Q
Annual filings:
10-K
Sedol: BP0WH76
Valuation (See tab for details)
PE ratio: 0.00
PB ratio: 0.00
PS ratio: 0.00
Return on equity: 0.00%
Net income %: 0.00%